Navigation Links
Inspire MD Announce the MASTER (MGUARD for Acute ST Elevation Reperfusion) Randomized Trial in TCT2010. Study Chairman Will be Dr. Gregg Stone
Date:9/24/2010

Inspire MD Announce the MASTER (MGUARD for Acute ST Elevation Reperfusion)... -- TCT 2010, WASHINGTON, September 24, 2010 /PRNewswire/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals, Personnel Announcements, Trade Show News, Clinical Trials & Medical Discoveries Click to view news release full screen  

Inspire MD Announce the MASTER (MGUARD for Acute ST Elevation Reperfusion) Randomized Trial in TCT2010. Study Chairman Will be Dr. Gregg Stone

 

TCT 2010, WASHINGTON, September 24, 2010 /PRNewswire/ -- InspireMD announced today the launch of a multinational randomized controlled trial designed to demonstrate MGuard Coronary Stent's superiority over standard care for STEMI (heart attack) patients.

The MASTER (MGUARD for Acute ST Elevation Reperfusion) Randomized Trial will enroll 406 patients in a 2-arm, parallel design, with a primary endpoint of complete ST segment resolution post procedure. Clinical follow-up will continue for 1 year and other important secondary endpoints will be measured. Dr. Gregg Stone, Director of Cardiovascular Research and Education from the Columbia University in New-York, who will serve as a study chairman, said "Too often primary PCI in patients with heart attack results in suboptimal blood flow to the heart muscle, resulting in excessive heart damage. We are hopeful that this trial will demonstrate that the MGuard technology improves the success rate of PCI and clinical outcomes in patients with heart attacks."

Mr. Ofir Paz, CEO of InspireMD said "The initiation of this trial is a very important milestone in our continuous effort to supply compelling evidence based information on MGuard to the cardiology community. We are committed to pursue our clinical program and demonstrate MGuard superiority over standard care."

The trial will run in Europe, South America and Israel with principal investigators, Dr. Alexandre Abizaid, Dr. Dariusz Dudek and Prof. Chaim Lotan.

About MGuard(TM) Coronary

MGuard(TM) presents a novel combination of a coronary stent merged with an embolic protection specifically designed for Acute MI patients. The embolic protection is comprised of an ultra-thin polymer mesh sleeve that wraps the stent. The MGuard(TM) coronary stent provides permanent embolic protection, without affecting deliverability. MGuard(TM) is CE Mark approved. The MGuard(TM) Coronary's innovative concept has enjoyed an enthusiastic welcome from leading interventional cardiologists around the world.

About InspireMD

InspireMD is an innovative medical device company focusing on the development and commercialization of its proprietary stent system technology, MGuard(TM). The company intends to apply its technology to develop products used in interventional cardiology and other vascular procedures. InspireMD's mission is to utilize its proprietary technology to make its products the industry standard for stents and to provide a superior solution to the key clinical issues of current stenting: restenosis, embolic showers, and late thrombosis. In addition to providing embolic protection and minimizing arterial injury, this promising technology can be an effective and uniform drug delivery mechanism with the help of the novel micron-level net for next generation drug eluting stents. InspireMD intends to pursue applications of this technology both for bare metal and drug eluting stents in coronary, carotid and peripheral artery procedures.

Contact details: http://www.inspire-md.com Jonina Ohayon Marketing Director Tel +972-52-5791120 jonina@inspire-md.com
'/>"/>

SOURCE Inspire MD
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Inspired by a cotton candy machine, engineers put a new spin on creating tiny nanofibers
2. Haydon Kerk Motion Solutions Inspires Next Generation of Innovators as Silver Supplier of the FIRST Robotics Competition
3. InspireMD Announces the Enrollment of the 1st Patient in the MGuard(TM) Israeli Registry. InspireMD Will Also Sponsor a Satellite Program Breakfast Meeting at the TCT Conference on September 24th 2009 in the Moscone Exhibition Center in San Francisco
4. InspireMD Announce the Completion of Enrollment for the MAGICAL Trial (MGuard(TM) in Acute Myocardial Infarction) at EuroPCR 09. Results Will be Presented May 21st by Dr. Dariusz Dudek at the InspireMD Cocktail Reception Debate Chaired by Prof. Martin Le
5. MGuard(TM), InspireMDs Novel Coronary Stent System, was Celebrated by World Leading Interventional Cardiologists at the Transcatheter Cardiovascular Therapeutics (TCT) in Washington DC, USA, October 12-17 2008
6. Suzanne Somers, Renowned Author, Medical Advocate, and Official Spokesperson for NeoStem, Inc., Inspires the Audience on The Ellen Degeneres Show
7. InspireMD Announces Enrollment of First Patients in the MGuard(TM) Acute Myocardial Infarction Clinical Trial Data Will be Used to Confirm Initial Positive Results
8. $1.6 Million Agreement to Accelerate Fragile X Research, Inspire Hope
9. ONCOTHYREON ANNOUNCES PRICING OF $14.9 MILLION PRIVATE PLACEMENT
10. GeneLink Announces HelixLife Private Label Distribution Agreement
11. SCARGUARD LABS, LLC Announces Key Consumption Results Fastest Growing Brand and Second in Total Rankings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... Three-Year Initiative Supports Next Generation of Medical Geneticists ... Camp Experiences SHPG ... lives of children born with rare diseases, as well as the ... announcing a new initiative designed to positively affect the lives of ... rare disease care. --> To mark the company,s founding ...
(Date:2/8/2016)... , Feb. 8, 2016 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ... top ten finalists for clean technology companies in the TSX ... top 10 companies listed on the TSX Venture Exchange, in ... gas, clean technology & life sciences, diversified industries ... weighting given to return on investment, market cap growth, trading ...
(Date:2/8/2016)... 8, 2016 --> ... an innovation-driven oncology company developing next generation cancer ... today announced that chairman emeritus of Tata Sons ... the company as part of the first close ... investors Navam Capital and Aarin Capital. ...
(Date:2/8/2016)... Feb. 8, 2016  BioElectronics Corporation (OTC Pink: ... announced today that it is responding to a ... the Securities and Exchange Commission posted on the ... Chairman of the Board of BioElectronics Corporation and ... Administration at The Fuqua School of Business, Duke ...
Breaking Biology Technology:
(Date:2/3/2016)... 4, 2016 --> --> ... M (105.0), up 1,187% compared with fourth quarter of 2014. ... 517.6 M (loss: 30.0). Earnings per share increased to SEK ... 537.4 M (neg: 74.7). , --> ... to SEK 2,900.5 M (233.6), up 1,142% compared with 2014. ...
(Date:2/3/2016)... 2016 Vigilant Solutions announces today that the ... Missouri solved two recent hit-and-run cases ... from Vigilant Solutions. Brian Wenberg explains, ... victim was walking out of a convenience store and witnessed an elderly male ... vehicle, striking his vehicle and leaving the scene.  In ...
(Date:2/2/2016)... Feb. 2, 2016  BioMEMS devices deployed ... focused on medical screening and diagnostic applications, ... Wearable devices that facilitate and assure continuous ... movement are being bolstered through new opportunities ... signal acquisition coupled with wireless connectivity and ...
Breaking Biology News(10 mins):